IOVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Iovance Stockholders and Encourages Investors to Contact the Firm

Group 1 - Iovance Biotherapeutics reported a significant decline in first quarter 2025 product revenue, totaling $49.3 million compared to $73.7 million in the previous quarter [2] - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, indicating a reduction of over 40% at the midpoint [2] - The revenue guidance revision was attributed to recent launch dynamics of the T cell immunotherapy, Amtagvi® (lifileucel), which was launched in the U.S. in the first half of 2024 [2] Group 2 - Following the announcement of the financial results and guidance revision, Iovance's stock experienced a drop on unusually heavy trading volume [2] - Bragar Eagel & Squire, P.C. is investigating potential claims against Iovance on behalf of stockholders regarding possible violations of federal securities laws and unlawful business practices [1]